Press releases

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis...

Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston...

MARLBOROUGH, Mass. and LAS VEGAS, Jan. 20, 2024 – Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the SOLIS randomized control trial, demonstrating...

MARLBOROUGH, Mass., Jan. 11, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced the company’s clinical data that will be featured at the 27th North American Neuromodulation...

Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass., Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation...

Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a...

Recent healthcare plan coverage of Intracept® system expands access to vertebrogenic pain treatment for tens of millions of patients MARLBOROUGH, Mass., Nov. 17, 2023 /PRNewswire/ -- Boston...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis...

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ --...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ --...